resectable esophageal
Recently Published Documents


TOTAL DOCUMENTS

335
(FIVE YEARS 107)

H-INDEX

30
(FIVE YEARS 4)

2022 ◽  
Vol 11 ◽  
Author(s):  
Jie Zhu ◽  
Jin Tao ◽  
Zhen Dai ◽  
Yan Tan ◽  
Li Jiang ◽  
...  

To investigate literature-based evidence regarding progression-free survival (PFS) as an early efficacy endpoint in patients with resectable esophageal or gastroesophageal junction (GEJ) cancer receiving neoadjuvant therapy, this study identified large-scale randomized controlled trials (RCTs) with strict quality control. Twenty-four RCTs involving 7,514 patients were included. Trial-level correlation analysis was conducted to analyze the relationship between PFS hazard ratio (HR) and overall survival (OS) HR, Δ median PFS and Δ median OS. Correlation analysis at the neoadjuvant treatment arm level was performed between 1- to 5-year PFS and 5-year OS, median PFS and median OS. Subgroup analysis was performed in patients treated with standard neoadjuvant chemoradiotherapy (NCRT). The correlation was evaluated using the Pearson correlation coefficient r in weighted linear regression, with weight equal to patient size. In trial-level correlation, PFS were strongly associated with OS HR (r, 0.82 [95% confidence interval (CI), 0.42-0.97]) and Δ median survival (r, 0.83 [95% CI, 0.54-0.96]). In neoadjuvant treatment arms, there was a strong correlation between 1 to 5-year PFS rates and 5-year OS (r, 0.83-0.95), and median PFS and median OS (r, 0.97 [95% CI, 0.85-0.99]). NCRT subgroup analysis demonstrated acceptable consistency. In conclusion, we recommend PFS as an early efficacy endpoint in resected esophageal or GEJ cancer treated with neoadjuvant therapy.


2021 ◽  
pp. 101707
Author(s):  
Wei Gilis Sheng ◽  
Emerline Assogba ◽  
Oumar Billa ◽  
Bernard Meunier ◽  
Johan Gagnière ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5834
Author(s):  
Wolfgang Schröder ◽  
Suzanne S. Gisbertz ◽  
Daan M. Voeten ◽  
Christian A. Gutschow ◽  
Hans F. Fuchs ◽  
...  

Transthoracic esophagectomy is currently the predominant curative treatment option for resectable esophageal adenocarcinoma. The majority of carcinomas present as locally advanced tumors requiring multimodal strategies with either neoadjuvant chemoradiotherapy or perioperative chemotherapy alone. Minimally invasive, including robotic, techniques are increasingly applied with a broad spectrum of technical variations existing for the oncological resection as well as gastric reconstruction. At the present, intrathoracic esophagogastrostomy is the preferred technique of reconstruction (Ivor Lewis esophagectomy). With standardized surgical procedures, a complete resection of the primary tumor can be achieved in almost 95% of patients. Even in expert centers, postoperative morbidity remains high, with an overall complication rate of 50–60%, whereas 30- and 90-day mortality are reported to be <2% and <6%, respectively. Due to the complexity of transthoracic esophagetomy and its associated morbidity, esophageal surgery is recommended to be performed in specialized centers with an appropriate caseload yet to be defined. In order to reduce postoperative morbidity, the selection of patients, preoperative rehabilitation and postoperative fast-track concepts are feasible strategies of perioperative management. Future directives aim to further centralize esophageal services, to individualize surgical treatment for high-risk patients and to implement intraoperative imaging modalities modifying the oncological extent of resection and facilitating surgical reconstruction.


2021 ◽  
Author(s):  
Tanya T.D. Soeratram ◽  
Aafke Creemers ◽  
Sybren L. Meijer ◽  
Onno J. Boer ◽  
Wim Vos ◽  
...  

2021 ◽  
Vol 9 (22) ◽  
pp. 1700-1700
Author(s):  
Hongtao Duan ◽  
Tianhu Wang ◽  
Zhilin Luo ◽  
Xiaoyuan Wang ◽  
Honggang Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document